Electroplated Electrodes for Continuous and Mass-Efficient Electrochemical Hydrogenation.

Chemistry

Abteilung Elektrosynthese, Fraunhofer Institut für Umwelt-, Sicherheits-und Energietechnik UMSICHT, Osterfelder Straße 3, 46047, Oberhausen, Germany.

Published: March 2024

Electrocatalytic hydrogenations (ECH) enable the reduction of organic substrates upon usage of electric current and present a sustainable alternative to conventional processes if green electricity is used. Opposed to most current protocols for electrode preparation, this work presents a one-step binder- and additive-free production of silver- and copper-electroplated electrodes. Controlled adjustment of the preparation parameters allows for the tuning of catalyst morphology and its electrochemical properties. Upon optimization of the deposition protocol and carbon support, high faradaic efficiencies of 93 % for the ECH of the Vitamin A- and E-synthon 2-methyl-3-butyn-2-ol (MBY) are achieved that can be maintained at current densities of 240 mA cm and minimal catalyst loadings of 0.2 mg cm, corresponding to an unmatched production rate of 1.47 kg g  h. For a continuous hydrogenation process, the protocol can be directly transferred into a single-pass operation mode giving a production rate of 1.38 kg g  h. Subsequently, the substrate spectrum was extended to a total of 17 different C-C-, C-O- and N-O-unsaturated compounds revealing the general applicability of the reported process. Our results lay an important groundwork for the development of electrochemical reactors and electrodes able to directly compete with the palladium-based thermocatalytic state of the art.

Download full-text PDF

Source
http://dx.doi.org/10.1002/chem.202303808DOI Listing

Publication Analysis

Top Keywords

production rate
8
electroplated electrodes
4
electrodes continuous
4
continuous mass-efficient
4
mass-efficient electrochemical
4
electrochemical hydrogenation
4
hydrogenation electrocatalytic
4
electrocatalytic hydrogenations
4
hydrogenations ech
4
ech enable
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Actinogen Medical, Sydney, Australia.

Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.

View Article and Find Full Text PDF

Background: SHIP1 is a phosphatidyl inositol phosphatase encoded by INPP5D, which has been identified as a risk gene for Alzheimer's disease (AD). SHIP1 is expressed in microglia, the resident macrophage in brain. It is a complex, multidomain protein that acts as a negative regulator downstream from TREM2.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Division of Neurodegenerative Disorders, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada.

Background: Alzheimer's disease (AD) is a neurodegenerative disorder primarily associated with aging, but manifests as a complex interplay of multiple factors. Decline in sex-hormones, particularly 17-beta estradiol, is linked to the aging process. The risk for onset of AD significantly increases with aging and loss of estradiol.

View Article and Find Full Text PDF

Background: Reactive astrocytes and neuron death by excitotoxicity are observed in Alzheimer's disease (AD). DHA-H (2-hydroxy-docosahexaenoic acid; 2-OH-C22:6 n-3) is a molecule under development that has demonstrated therapeutic efficacy in both cellular and 5xFAD mouse model of AD. DHA-H is metabolized through α-oxidation to yield HPA (Heneicosapentaenoic acid; C21:5 n-3).

View Article and Find Full Text PDF

Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

December 2024

UK Dementia Research Institute, Care Research and Technology Centre, Imperial College London and the University of Surrey, Guildford, United Kingdom.

Background: Changes in sleep patterns are common in Alzheimer's disease and impact the quality of life of both people living with Alzheimer's (PLWA) and their caregivers. Longitudinal recordings and assessment of night-to-night variations in sleep and physiology can improve our understanding of how sleep influences clinical outcomes and caregiver wellbeing.

Method: We collected sleep diary and contactless sleep technology data (Withings sleep analyser, WSA) in community dwelling PLWA (N = 16, Age = 72.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!